How Pharmaceutical War Games Move from Insight to Action
Pharmaceutical competition now unfolds across more than brand-versus-brand positioning. Franchise priorities, portfolio choices, corporate commitments and a wider set of stakeholders than the commercial team alone can shape a launch. That changes what a war game has to accomplish. A useful simulation cannot stop at predicting a rival’s next move. It has to help teams decide what game they intend to play and where they can influence the market before launch. The session must also narrow down the actions that deserve resources once the workshop ends.
Simulation design is therefore a major buying factor. Standard templates can make workshops easier to run, but they may flatten differences in an asset’s specific market context. The design should also reflect the company’s internal decision structure and bring in functions that can materially alter the strategy. The exercise should test competition beyond the most visible branded rivals. Market inertia, generics, payer behavior and other forces can change the route to adoption, even when none looks like a conventional competitor. Preparation matters just as much. Background material should be selective enough that participants arrive focused on information that can change a decision rather than carrying a large research packet into the room.
Another factor is whether the session produces usable strategic direction rather than a collection of observations. Competitive insight has limited value when participants leave with different interpretations of what matters. Effective war games narrow the field. Teams need a concise campaign agenda that frames the market around a position the company can sustain. A common communications platform can then give functions and markets a shared narrative. The remaining work is execution. Prioritized moves should translate that strategy into work that can be assigned and carried into planning after debate, rather than becoming another workshop document.
“Bernard Associates also considers competition at brand, franchise, portfolio and corporate levels rather than limiting the exercise to brand rivals.”
Timing creates a further distinction. Competitive preparation that begins only around approval leaves little room to influence how the market understands the product. Pharmaceutical teams often have years of prelaunch activity in which to shape scientific discussion and stakeholder expectations. Internal coordination must begin early enough to support that work. A war game should connect with broader launch planning instead of sitting apart as a one-time event. Senior participation can also change the usefulness of the exercise because decisions about resources and tradeoffs may sit above the brand team. Role play is most useful when participants experience both the competitor’s logic and their own company’s response rather than defending one position throughout the session.
Bernard Associates builds its Pharma 2.0 War Games around customized simulations developed with a cross-functional design team, supported by focused preparation before the live session. Participants role-play competitors before returning to the client perspective, while senior executives remain involved through the exercise. The process develops a campaign agenda to define the game the company wants to play. A common communications platform follows, giving functions and markets a shared narrative. Prioritized winning actions then carry the strategy into planning. Bernard Associates also considers competition at brand, franchise, portfolio and corporate levels rather than limiting the exercise to brand rivals. For buyers who want pharmaceutical war games to move beyond competitive observation into coordinated market action, Bernard Associates merits consideration.
